Navigation Links
Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Date:8/19/2010

LONDON, Aug. 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

Quark is currently conducting a Phase II clinical trial of QPI-1002 for the prevention of acute kidney injury in patients undergoing cardiac surgery and for delayed graft function in kidney transplant patients.  Based on the announcement issued by Quark on 18 August 2010, and under the terms of Silence's agreement with Quark, Silence anticipates that its future milestone payments from this program could potentially exceed $65 million.    

Commenting on today's announcement, Phil Haworth, CEO of Silence, said: "We are delighted that Novartis has chosen to take this development option for QPI-1002.  This serves as further validation of Silence's leading AtuRNAi technology and we look forward to receiving the significant milestones as the development of QPI-1002 continues."

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a libra
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has selected an optimized Erk inhibitor molecule for ... development of a new class of potential cancer ... a prime target for therapeutic intervention in cancer. ... survival benefits for B-Raf and Mek inhibitors. Erk ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead ... to protect the Orange County, Texas area from future storm surge flooding, such ... in determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... making good progress in evaluating the full range of capabilities of its unique ... tissue stem cells perform the day-to-day renewal and repair of normal tissues and ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... 20 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... its financial results for the quarter,ended December 31, 2007., ... recorded net revenue of,$288.0 million compared to net revenue ... revenue increase was primarily due to increased,product sales in ...
... OSTE ), a leader in the emerging field of ... for the year,ending December 31, 2007 increased 5% to ... December 31, 2006. Revenue from "core" product,lines, DBM and ... increase of 15% over core product revenue of $58.8 ...
... Today at 10:00 CET, AMSTERDAM, February 20 Amsterdam Molecular,Therapeutics ... reported its full year 2007 results., Highlights ... - Cash & cash equivalents of EUR 51.3 million at ... lead product AMT 011 - Positive results of Phase I/II ...
Cached Biology Technology:Inverness Medical Innovations Announces Fourth Quarter 2007 Results 2Inverness Medical Innovations Announces Fourth Quarter 2007 Results 3Inverness Medical Innovations Announces Fourth Quarter 2007 Results 4Inverness Medical Innovations Announces Fourth Quarter 2007 Results 5Inverness Medical Innovations Announces Fourth Quarter 2007 Results 6Inverness Medical Innovations Announces Fourth Quarter 2007 Results 7Inverness Medical Innovations Announces Fourth Quarter 2007 Results 8Inverness Medical Innovations Announces Fourth Quarter 2007 Results 9Inverness Medical Innovations Announces Fourth Quarter 2007 Results 10Inverness Medical Innovations Announces Fourth Quarter 2007 Results 11Inverness Medical Innovations Announces Fourth Quarter 2007 Results 12Inverness Medical Innovations Announces Fourth Quarter 2007 Results 13Inverness Medical Innovations Announces Fourth Quarter 2007 Results 14Inverness Medical Innovations Announces Fourth Quarter 2007 Results 15Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 2Amsterdam Molecular Therapeutics Reports Full Year Results 2007 3Amsterdam Molecular Therapeutics Reports Full Year Results 2007 4Amsterdam Molecular Therapeutics Reports Full Year Results 2007 5Amsterdam Molecular Therapeutics Reports Full Year Results 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 7
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... HILO, HawaiiA team of scientists from the ... and two universities will begin research using sophisticated ... that have the most potential for ecological restoration. ... Susan Cordell, PSW research ecologist; Dr. Erin Questad, ...
... Jan. 24, 2012 Ingenuity Systems, a leading ... science researchers, today announced the general availability of ... fastest way to get biological meaning from expression ... for the statistical analysis and biological interpretation of ...
... recent Van Andel Research Institute (VARI) study published in the journal ... essential plant hormone could profoundly change our understanding of a key ... drugs for a variety of diseases. The study builds ... that was published in the journal Nature in 2009. ...
Cached Biology News:High-tech models help guide restoration efforts to save threatened plants 2Ingenuity Systems iReport Now Available: Fast, Accurate, Interactive Report for Gene Expression Data 2
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... Disposable, clear, APET plastic tray. Ideal ... identify those trays used for multipurposes. Pour ... liquid. A marker or label may be ... stacking trays on rockers or shakers for ...
ID clarifier: non-treated with lid...
... The Staccato Series of systems provide fast and reliable ... and drug development laboratories. Staccato systems are available in ... Custom Systems Series. ... All ...
Biology Products: